Ferreira I J, Escosa L, Casasnovas J A, Barrios S J, Marcos J M, Pardell H, Navarro A, de la Fuente V
An Med Interna. 1989 Mar;6(3):128-32.
The aim of the present study was to determine both the effectiveness and tolerance of a preparation constituted by the combination at fixed doses of a betablocker (atenolol, 100 mg), a diuretic (bendroflumethiazide, 5 mg) and a vasodilator (hydralazine, 50 mg). The study was carried out on a sample formed by 46 patients with moderate or severe essential hypertension who received this preparation as a single antihypertensive therapy during 2 months. As for the hypotensive effectiveness of the product, obtained results demonstrate that arterial blood pressure (BP) levels were normalized in 89% of the patients with moderate essential hypertension and in 9/10 patients with severe hypertension. Tolerance was excellent in most of the cases. Although new studies should be performed in order to enlarge the number of available case-studies, the above presented data allow us to conclude with a positive opinion about the studied combination.
本研究的目的是确定一种由固定剂量的β受体阻滞剂（阿替洛尔，100毫克）、利尿剂（苄氟噻嗪，5毫克）和血管扩张剂（肼屈嗪，50毫克）组合而成的制剂的有效性和耐受性。该研究对46例中度或重度原发性高血压患者进行，这些患者在2个月内接受该制剂作为单一抗高血压治疗。至于该产品的降压效果，所得结果表明，89%的中度原发性高血压患者和9/10的重度高血压患者的动脉血压（BP）水平恢复正常。在大多数情况下耐受性良好。尽管应该进行新的研究以扩大现有病例研究的数量，但上述数据使我们能够对所研究的组合给出积极的评价。
